Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications cost effectiveness adjuvanted recombinant zoster vaccine older adults united states who
… Is Investment to Increase Vaccination in Older Adults Worth the Cost? Share on: October 5, 2021 Gaining optimal vaccination … recommend that older adults in the US be vaccinated for vaccine-preventable influenza, whooping cough, shingles, and …
… for Population Therapeutics Conference. Updated cost-utility and public health impact of recombinant zoster vaccine (RZV) in Canadians aged 50 years … K, Loukov D, Kaan I, Ng C, Regan J, Giannelos N. Cost-effectiveness and public health impact of recombinant zoster …
… health goals. Given the human and economic burden of vaccine-preventable disease, understanding the factors behind … studied included seasonal influenza; pneumococcal; herpes zoster; and tetanus, diphtheria, and acellular pertussis. … is needed to further explain the variations between states. However, results from this recent study provide …
… the 8th ReSViNET Conference. Public health impact of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among older adults in the United States. Molnar D, La EM, Verelst …
… be presented at the 2023 Canadian Immunization Conference. Cost-effectiveness and public health impact of recombinant zoster vaccine in immunocompromised adults in …
… team has built hundreds of models, including: Cost-effectiveness models Budget impact models Cost-consequence … analysis Our Approach From design to deliverables, publications , and ongoing support, we develop and validate …
… Award for Research on Breast Cancer Treatment for Older Patients Share on: July 10, 2023 Guideline-Based … the first population-based observational study in the United States assessing the success of CDK4/6 inhibitors in … patients with HR+/HER2– metastatic breast cancer. Links to publications: Goyal RK, Chen H, Abughosh SM, Holmes HM, …
… in your study will benefit more or less than the average. Who are they and can they be identified efficiently? To … a thorough exploration and understanding of subgroups who benefit more from treatment. Understanding subgroup …
… Cross-Sectional Survey of Pneumococcal Vaccine Prescribers OPPORTUNITY The CDC’s Advisory Committee … to pneumococcal disease immunization recommendations among adults aged ≥ 65 years. OUR APPROACH We conducted a cross-sectional survey among US HCPs who prescribe and administer pneumococcal vaccine to adults …
… and pertussis (Tdap) Typhoid Typhoid fever Varicella Zoster Types of Projects We have implemented studies to help … studies Conjoint analyses Decision-analytic models (cost effectiveness, budget impact) Dynamic disease transmission …